{"pmid":32033513,"title":"[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","text":["[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together.","Zhonghua Yi Xue Za Zhi","Lin, L","Li, T S","32033513"],"abstract":["the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together."],"journal":"Zhonghua Yi Xue Za Zhi","authors":["Lin, L","Li, T S"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32033513","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.0376-2491.2020.0001","keywords":["2019 Novel coronavirus","guidelines","pneumonia"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647055937536,"score":6.7365713,"similar":[{"pmid":32098466,"title":"[What are the highlights of \"Diagnosis and treatment of Disease 2019 novel coronavirus infection suitable for Military support Hubei medical team\"].","text":["[What are the highlights of \"Diagnosis and treatment of Disease 2019 novel coronavirus infection suitable for Military support Hubei medical team\"].","Thousands of medical workers in the Military support Hubei medical team are exerting themselves in many hospitals in Hubei Province. They are diligent in treating patients, at the same time, they constantly summarize experience and combine the characteristics of military hospitals. According to \" the Diagnosis and Treatment of New Coronavirus Pneumonia \"(6th edition) of the National Health Commission of the People's Republic of China, a new guideline for the diagnosis and treatment of 2019 novel coronavirus infection suitable for the military (first trial version) was established. Some unique opinions and suggestions are put forward in terms of disease name, diagnosis criteria, antiviral treatment, glucocorticoid application, etc. This article will make a proper interpretation in order to understand the guideline better and help guide the diagnosis and treatment of diseases.","Zhonghua Jie He He Hu Xi Za Zhi","Shi, Y","32098466"],"abstract":["Thousands of medical workers in the Military support Hubei medical team are exerting themselves in many hospitals in Hubei Province. They are diligent in treating patients, at the same time, they constantly summarize experience and combine the characteristics of military hospitals. According to \" the Diagnosis and Treatment of New Coronavirus Pneumonia \"(6th edition) of the National Health Commission of the People's Republic of China, a new guideline for the diagnosis and treatment of 2019 novel coronavirus infection suitable for the military (first trial version) was established. Some unique opinions and suggestions are put forward in terms of disease name, diagnosis criteria, antiviral treatment, glucocorticoid application, etc. This article will make a proper interpretation in order to understand the guideline better and help guide the diagnosis and treatment of diseases."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Shi, Y"],"date":"2020-02-27T11:00:00Z","year":2020,"_id":"32098466","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112147-20200225-00183","keywords":["Military","diagnosis and treatment","infection","medical team","novel coronavirus"],"source":"PubMed","locations":["Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647462785024,"score":211.99525},{"pmid":32074550,"title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.","text":["Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.","The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.","Biosci Trends","Gao, Jianjun","Tian, Zhenxue","Yang, Xu","32074550"],"abstract":["The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future."],"journal":"Biosci Trends","authors":["Gao, Jianjun","Tian, Zhenxue","Yang, Xu"],"date":"2020-02-20T11:00:00Z","year":2020,"_id":"32074550","week":"20208|Feb 17 - Feb 23","doi":"10.5582/bst.2020.01047","keywords":["2019-nCoV","COVID-19","SARS-CoV-2","chloroquine","pneumonia"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647342198784,"score":166.15747},{"pmid":32111114,"title":"[Recommendations for the regulation of medical practices of burn treatment during the outbreak of the coronavirus disease 2019].","text":["[Recommendations for the regulation of medical practices of burn treatment during the outbreak of the coronavirus disease 2019].","2019 novel coronavirus (2019-nCoV) is one of the beta coronaviruses and was identified as the pathogen of the severe \"coronavirus disease 2019 (COVID-19)\" in 2019. China has formally included the 2019-nCoV in the statutory notification and control system for infectious diseases according to the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases. Currently, the national defending actions on the 2019-nCoV in China is in a critical period. Burn Department is also confronted with risk of infection by the 2019-nCoV. According to the guidelines on the diagnosis and treatment of COVID-19 (6(th) trial edition), the latest relative literature at home and abroad, the features of the COVID-19, recommendations for the COVID-19 prevention and control issued by the National Health Commission of China, and management experience of diagnosis and treatment in the related disciplines, we put forward recommendations for the medical practices of burn treatment during the outbreak of the COVID-19 in outpatient and emergency treatment, inpatient treatment, operation and ward management, etc. We hope these recommendations could benefit the professionals of the same occupation as us and related hospital managers, improve the treatment of burn during the outbreak of the COVID-19, and avoid or reduce the risk of infection of medical staff .","Zhonghua Shao Shang Za Zhi","Ma, S Y","Yuan, Z Q","Peng, Y Z","Luo, Q Z","Song, H P","Xiang, F","Tan, J L","Zhou, J Y","Li, N","Hu, G Z","Luo, G X","32111114"],"abstract":["2019 novel coronavirus (2019-nCoV) is one of the beta coronaviruses and was identified as the pathogen of the severe \"coronavirus disease 2019 (COVID-19)\" in 2019. China has formally included the 2019-nCoV in the statutory notification and control system for infectious diseases according to the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases. Currently, the national defending actions on the 2019-nCoV in China is in a critical period. Burn Department is also confronted with risk of infection by the 2019-nCoV. According to the guidelines on the diagnosis and treatment of COVID-19 (6(th) trial edition), the latest relative literature at home and abroad, the features of the COVID-19, recommendations for the COVID-19 prevention and control issued by the National Health Commission of China, and management experience of diagnosis and treatment in the related disciplines, we put forward recommendations for the medical practices of burn treatment during the outbreak of the COVID-19 in outpatient and emergency treatment, inpatient treatment, operation and ward management, etc. We hope these recommendations could benefit the professionals of the same occupation as us and related hospital managers, improve the treatment of burn during the outbreak of the COVID-19, and avoid or reduce the risk of infection of medical staff ."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Ma, S Y","Yuan, Z Q","Peng, Y Z","Luo, Q Z","Song, H P","Xiang, F","Tan, J L","Zhou, J Y","Li, N","Hu, G Z","Luo, G X"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32111114","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn501120-20200224-00083","keywords":["Burns","Coronavirus disease 2019","Epidemic prevention and control","Recommendations for diagnosis and treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647960858624,"score":146.13081},{"pmid":32057209,"title":"[Pharmacotherapeutics for the New Coronavirus Pneumonia].","text":["[Pharmacotherapeutics for the New Coronavirus Pneumonia].","The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-alpha is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.","Zhonghua Jie He He Hu Xi Za Zhi","Du, B","Qiu, H B","Zhan, X","Wang, Y S","Kang, H Y J","Li, X Y","Wang, F","Sun, B","Tong, Z H","32057209"],"abstract":["The New Coronavirus Pneumonia (NCP, also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new Coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new Coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and Interferon-alpha is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg.kg(-1).d(-1), 3~5d ) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Du, B","Qiu, H B","Zhan, X","Wang, Y S","Kang, H Y J","Li, X Y","Wang, F","Sun, B","Tong, Z H"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32057209","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0012","keywords":["Antibiotics","Glucocorticosteroid","New coronavirus pneumonia","Pharmacotherapeutics"],"source":"PubMed","locations":["Interferon-alpha","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647284527104,"score":140.99998},{"pmid":32034659,"title":"Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.","text":["Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.","Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Wuhan City, China, by January 30, 2020, a total of 9692 confirmed cases and 15,238 suspected cases have been reported around 31 provinces or cities in China. Among the confirmed cases, 1527 were severe cases, 171 had recovered and been discharged at home, and 213 died. And among these cases, a total of 28 children aged from 1 month to 17 years have been reported in China. For standardizing prevention and management of 2019-nCoV infections in children, we called up an experts' committee to formulate this experts' consensus statement. This statement is based on the Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards (the fourth edition) (National Health Committee) and other previous diagnosis and treatment strategies for pediatric virus infections. The present consensus statement summarizes current strategies on diagnosis, treatment, and prevention of 2019-nCoV infection in children.","World J Pediatr","Shen, Kunling","Yang, Yonghong","Wang, Tianyou","Zhao, Dongchi","Jiang, Yi","Jin, Runming","Zheng, Yuejie","Xu, Baoping","Xie, Zhengde","Lin, Likai","Shang, Yunxiao","Lu, Xiaoxia","Shu, Sainan","Bai, Yan","Deng, Jikui","Lu, Min","Ye, Leping","Wang, Xuefeng","Wang, Yongyan","Gao, Liwei","32034659"],"abstract":["Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Wuhan City, China, by January 30, 2020, a total of 9692 confirmed cases and 15,238 suspected cases have been reported around 31 provinces or cities in China. Among the confirmed cases, 1527 were severe cases, 171 had recovered and been discharged at home, and 213 died. And among these cases, a total of 28 children aged from 1 month to 17 years have been reported in China. For standardizing prevention and management of 2019-nCoV infections in children, we called up an experts' committee to formulate this experts' consensus statement. This statement is based on the Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards (the fourth edition) (National Health Committee) and other previous diagnosis and treatment strategies for pediatric virus infections. The present consensus statement summarizes current strategies on diagnosis, treatment, and prevention of 2019-nCoV infection in children."],"journal":"World J Pediatr","authors":["Shen, Kunling","Yang, Yonghong","Wang, Tianyou","Zhao, Dongchi","Jiang, Yi","Jin, Runming","Zheng, Yuejie","Xu, Baoping","Xie, Zhengde","Lin, Likai","Shang, Yunxiao","Lu, Xiaoxia","Shu, Sainan","Bai, Yan","Deng, Jikui","Lu, Min","Ye, Leping","Wang, Xuefeng","Wang, Yongyan","Gao, Liwei"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32034659","week":"20206|Feb 03 - Feb 09","doi":"10.1007/s12519-020-00343-7","source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647050694656,"score":110.63189}]}